Regeneron Pharmaceuticals

Latest statistics and disclosures from Regeneron Pharmaceuticals's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are Parabilis Medicines, NTLA, ACET, and represent 100.00% of Regeneron Pharmaceuticals's stock portfolio.
  • Added to shares of these 2 stocks: Parabilis Medicines (+$114M), ACET.
  • Started 2 new stock positions in Parabilis Medicines, ACET.
  • Reduced shares in these 1 stock: Adicet Bio.
  • Sold out of its position in Adicet Bio.
  • Regeneron Pharmaceuticals was a net buyer of stock by $114M.
  • Regeneron Pharmaceuticals has $177M in assets under management (AUM), dropping by 270.10%.
  • Central Index Key (CIK): 0000872589

Tip: Access up to 7 years of quarterly data

Positions held by Regeneron Pharmaceuticals consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Regeneron Pharmaceuticals

Regeneron Pharmaceuticals holds 3 positions in its portfolio as reported in the June 2026 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Parabilis Medicines Common Stock 64.4 $114M NEW 4.2M 27.37
 View chart
Intellia Therapeutics Common Stock (NTLA) 35.4 $63M 3.7M 16.92
 View chart
Adicet Bio Common Stock (ACET) 0.3 $523k NEW 61k 8.64
 View chart

Past Filings by Regeneron Pharmaceuticals

SEC 13F filings are viewable for Regeneron Pharmaceuticals going back to 2024